Family · Pharmaceutical analytical standards
Pimavanserin
A medicine acting on serotonin 5-HT2A receptors, approved in the United States in April 2016 as the first treatment for the hallucinations and delusions of psychosis associated with Parkinson's disease. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It is an inverse agonist: besides stopping serotonin from activating the 5-HT2A receptor, it also lowers the receptor's spontaneous activity, the activity it shows even without its messenger.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
